| pubmed-article:18336735 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18336735 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:18336735 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:18336735 | lifeskim:mentions | umls-concept:C0027819 | lld:lifeskim |
| pubmed-article:18336735 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:18336735 | lifeskim:mentions | umls-concept:C1413221 | lld:lifeskim |
| pubmed-article:18336735 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:18336735 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:18336735 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18336735 | pubmed:dateCreated | 2008-3-13 | lld:pubmed |
| pubmed-article:18336735 | pubmed:abstractText | Human CD38 antigen is a 42-45 kDa type II transmembrane glycoprotein with a short N-terminal cytoplasmic domain and a long C-terminal extracellular region. It is widely expressed in different cell types including thymocytes, activated T cells, and terminally differentiated B cells (plasma cells) and it is involved in cellular proliferation and adhesion. CD38 acts as an ectocyclase that converts NAD+ to the Ca2+ -releasing second messenger cyclic ADP-ribose (cADPR). It has been also demonstrated that increased extracellular levels of NAD+ and cADPR are involved in inflammatory diseases and in cellular damage, such as ischemia. In the present study, we have characterized the expression of CD38 in human neuroblastoma SH-SY5Y cell line. All-trans-retinoic acid (ATRA) treatment was used to induce cell differentiation. Our results indicate that: a) even if SH-SY5Y cells have a negative phenotype express CD38 at nuclear level, ATRA treatment does not influence this pattern; b) CD38 localizing to the nucleus may co-localize with p80-coilin positive nuclear-coiled bodies; c) purified nuclei, by Western blot determinations using anti-CD38 antibodies, display a band with a molecular mass of approximately 42 kDa; d) SH-SY5Y cells show nuclear ADP-ribosyl cyclase due to CD38 activity; e) the basal level of CD38 mRNA shows a time-dependent increase after treatment with ATRA. These results suggest that the presence of constitutive fully functional CD38 in the SH-SY5Y nucleus has some important implications for intracellular generation of cADP-ribose and subsequent nucleoplasmic calcium release. | lld:pubmed |
| pubmed-article:18336735 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18336735 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18336735 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18336735 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18336735 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18336735 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18336735 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18336735 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18336735 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18336735 | pubmed:issn | 0394-6320 | lld:pubmed |
| pubmed-article:18336735 | pubmed:author | pubmed-author:TrediciGG | lld:pubmed |
| pubmed-article:18336735 | pubmed:author | pubmed-author:Di PrimioRR | lld:pubmed |
| pubmed-article:18336735 | pubmed:author | pubmed-author:CavalettiGG | lld:pubmed |
| pubmed-article:18336735 | pubmed:author | pubmed-author:TrubianiOO | lld:pubmed |
| pubmed-article:18336735 | pubmed:author | pubmed-author:SalvoliniEE | lld:pubmed |
| pubmed-article:18336735 | pubmed:author | pubmed-author:GuarnieriSS | lld:pubmed |
| pubmed-article:18336735 | pubmed:author | pubmed-author:OrcianiMM | lld:pubmed |
| pubmed-article:18336735 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18336735 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:18336735 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18336735 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18336735 | pubmed:pagination | 97-105 | lld:pubmed |
| pubmed-article:18336735 | pubmed:meshHeading | pubmed-meshheading:18336735... | lld:pubmed |
| pubmed-article:18336735 | pubmed:meshHeading | pubmed-meshheading:18336735... | lld:pubmed |
| pubmed-article:18336735 | pubmed:meshHeading | pubmed-meshheading:18336735... | lld:pubmed |
| pubmed-article:18336735 | pubmed:meshHeading | pubmed-meshheading:18336735... | lld:pubmed |
| pubmed-article:18336735 | pubmed:meshHeading | pubmed-meshheading:18336735... | lld:pubmed |
| pubmed-article:18336735 | pubmed:meshHeading | pubmed-meshheading:18336735... | lld:pubmed |
| pubmed-article:18336735 | pubmed:meshHeading | pubmed-meshheading:18336735... | lld:pubmed |
| pubmed-article:18336735 | pubmed:articleTitle | Expression of CD38 in human neuroblastoma SH-SY5Y cells. | lld:pubmed |
| pubmed-article:18336735 | pubmed:affiliation | Department of Molecular Pathology and Innovative Therapies, Histology Section, Marche Polytechnic University, Ancona, Italy. | lld:pubmed |
| pubmed-article:18336735 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18336735 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
